Condition (MeSH)
Mumps
ClinicalTrials.gov lists 81 trials for Mumps or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 24.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
81 of the 81 trials are tagged with Mumps itself; the rest are tagged with a narrower condition beneath it.
When did Mumps trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 3 |
| 2017 | 1 |
| 2016 | 4 |
| 2015 | 3 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mumps trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 38 |
| Phase 4 | 16 |
| Not applicable | 2 |
| Observational | 12 |
How many Mumps trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 61 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mumps trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 24 |
| Merck Sharp & Dohme LLC | 18 |
| Sanofi Pasteur, a Sanofi Company | 5 |
| Sinovac (Dalian) Vaccine Technology Co., Ltd. | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Mumps? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| VARIVAX | 6 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| M-M-R II | 6 |
| Priorix | 6 |
| ProQuad | 6 |
| Havrix+Havrix | 5 |
| Comparator: M-M-R II | 5 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mumps trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Gastroenteritis | 148 | 24 |
| Pneumonia | 109 | 22 |
| Febrile convulsion | 106 | 21 |
| Bronchiolitis | 80 | 16 |
| Bronchitis | 66 | 9 |
Showing 5 of 10 adverse events.
Which publications cover Mumps? (45)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| MMR vaccination induces trained immunity via functional and metabolic reprogramming of γδ T cells. | The Journal of clinical investigation | 2024 | Yes |
| Mumps-specific antibody persistence in children aged 3-7 years immunized with two doses of mumps-containing vaccines: A prospective cohort study in Jiangsu Province, China. | Human vaccines & immunotherapeutics | 2023 | Yes |
| Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. | BMC infectious diseases | 2023 | Yes |
| Measles, mumps, and rubella vaccine at age 6 months and hospitalisation for infection before age 12 months: randomised controlled trial. | BMJ (Clinical research ed.) | 2023 | Yes |
| Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants. | Vaccine | 2022 | Yes |
Showing 5 of 45 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.